Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Around half a million Britons are now thought to be using the medication, which can help them lose up to 20 per cent of their ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...